<DOC>
	<DOCNO>NCT00716898</DOCNO>
	<brief_summary>The purpose study determine Pharmacokinetics Low Molecular Weight Heparin ( LMWH ) Cancer patient , compare Pharmacokinetics LMWH Patients without cancer . We also intend detect correlation heparanase blood urine level Pharmacokinetics LMWH .</brief_summary>
	<brief_title>Pharmacokinetics Low Molecular Weight Heparin Cancer Patients</brief_title>
	<detailed_description>Scientific background . The increase risk venous thromboembolism ( VTE ) cancer long recognize ( 1 ) . Since first describe Trousseau 1865 , many aspect complex relationship still obscure ( 2 ) . Cancer patient increase risk develop thrombosis . Similarly , patient present idiopathic VTE consider high risk develop cancer ( 3 ) . Approximately 10 % patient idiopathic VTE harbor underlie malignancy detect extensive diagnostic work-up ( 4 ) . Clinical data indicate cancer alone associate 4.1- fold risk thrombosis , chemotherapy increase risk 6.1- fold ( 5 ) . Cancer patient develop postoperative VTE least 2- fold patient without cancer undergo surgical procedure ( 6 ) . Treatment VTE involve administration heparin , low molecular weight heparin ( LMWH ) coumarin derivative . Beside anticoagulant effect , LMWH may also anti-tumoral effect ( 7-12 ) . The use LMWH relative coumarin derivative associate improved survival patient solid tumor metastatic disease time acute VTE ( 9 ) . Moreover , addition LMWH chemotherapy increase survival patient small cell lung cancer ( 10 ) . Heparan sulfate proteoglycans ( HSPGs ) ubiquitous macromolecule associate cell surface extracellular matrix ( ECM ) wide range cell vertebrate invertebrate tissue . Heparin structurally relate heparan sulfate ( HS ) , high N- O-sulfate content ( 13 ) . Mammalian endoglycosidase , capable partially depolymerizing HS chain commonly refer heparanase , identify variety cell type tissue , primarily cancer cell , activate cell immune system , platelet , placenta ( 14-17 ) . Heparanase synthesize latent 65 kDa precursor whose activation involve proteolytic cleavage two potential site locate N-terminal region molecule ( Glu109 -Ser110 Gln157 -lys158 ) , result formation two protein subunit heterodimerize form active heparanase enzyme ( 18 ) . Expression heparanase correlate metastatic potential human tumor cell ( 14-16 , 19 ) . Furthermore , elevated level heparanase detect urine patient aggressive metastatic disease ( 20 ) . Heparin , LMWH , non-anticoagulant chemically modified specie heparin ( 21 , 22 ) , well polysaccharide ( 23 , 24 ) inhibit experimental metastasis , also inhibit tumor cell heparanase , related compound small effect parameter ( 21-24 ) . Recently , demonstrate anticoagulant activity heparin LMWH neutralize pre-incubation heparanase . Transgenic mouse overexpressing heparanase , exhibit hyper-coagulable phenotype express markedly short base-line APTT compare control mouse ( 25 ) . These result may suggest resistance heparin , describe patient malignancy ( 26 , 27 ) , could attribute , part , high level heparanase often observe cell ( 28 , 29 ) body fluid ( 20 ) patient aggressive malignant disease . Degradation heparin LMWH heparanase vivo may relevant situation heparanase over-expressed , treatment heparin LMWH need ( e.g. , deep venous thrombosis patient pancreatic carcinoma ) ( 29 , 30 ) . The pharmacokinetics LMWH ( i.e . time course absorption , distribution , metabolism , degradation ) reflect effect upon factor Xa activity , elucidate several subgroup patient ( e.g . patient renal failure , pregnant womenâ€¦ ) , best knowledge address patient advance solid tumor . Objectives &amp; expect significance . In view describe biological significance heparanase enzyme , take account recent vitro vivo result ( heparanase capability cleave heparin LMWH ; alter coagulation profile transgenic mouse overexpressing heparanase ) ( 25 ) , propose focus follow specific aim : I ) Measure plasma urine heparanase level patient advance cancer suffer VTE , compare control without cancer . II ) Elucidate pharmacokinetics LMWH patient advance solid tumor ( AST ) suffer VTE , compare pharmacokinetics LMWH patient unstable angina pectoris . III ) Determine correlation heparanase blood level pharmacokinetics LMWH , . References 1 . Rickles FR . Mechanisms cancer-induced thrombosis cancer . Pathophysiol Haemost Thromb . 2006 ; 35 : 103-110 . 2 . Trousseau A : Phlegmasia alba dolens , : Clinique Medicale de l'Hotel Dieu de Paris . Vol 3 , ed 2 . Balliere , Paris , 1865 ; pp 654-712 . 3 . Valente M , Ponte E. Thrombosis cancer . Minerva Cardioangiol . 2000 ; 48 : 117-127 . 4 . Prandoni P. Cancer venous thromboembolism . Clinical implication strong association . Pathophysiol Haemost Thromb . 2006 ; 35 : 111-115 . 5 . Heit JA , Silverstein MD , Mohr DN , Petterson TM , O'Fallon WM , Melton LJ 3rd . Risk factor deep vein thrombosis pulmonary embolism : population-based case-control study . Arch Intern Med . 2000 ; 160 : 809-815 . 6 . Rickles FR , Levine MN . Epidemiology thrombosis cancer . Acta Haematol . 2001 ; 106 : 6-12 . 7. von Tempelhoff GF , Harenberg J , Niemann F , Hommel G , Kirkpatrick CJ , Heilmann L. Effect low molecular weight heparin ( Certoparin ) versus unfractionated heparin cancer survival follow breast pelvic cancer surgery : A prospective randomize double-blind trial . Int J Oncol . 2000 ; 16 : 815-824 . 8 . Kakkar AK , Levine MN , Kadziola Z , Lemoine NR , Low V , Patel HK , Rustin G , Thomas M , Quigley M , Williamson RC . Low molecular weight heparin , therapy dalteparin , survival advance cancer : fragmin advance malignancy outcome study ( FAMOUS ) . J Clin Oncol . 2004 ; 10 : 1944-1948 . 9 . Lee AY , Rickles FR , Julian JA , Gent M , Baker RI , Bowden C , Kakkar AK , Prins M , Levine MN . Randomized comparison low molecular weight heparin coumarin derivative survival patient cancer venous thromboembolism . J Clin Oncol . 2005 ; 23 : 2123-2129 . 10 . Altinbas M , Coskun HS , Er O , Ozkan M , Eser B , Unal A , Cetin M , Soyuer S. A randomize clinical trial combination chemotherapy without low-molecular-weight heparin small cell lung cancer . J Thromb Haemost . 2004 ; 2 : 1266-1271 . 11 . Klerk CP , Smorenburg SM , Otten HM , Lensing AW , Prins MH , Piovella F , Prandoni P , Bos MM , Richel DJ , van Tienhoven G , Buller HR . The effect low molecular weight heparin survival patient advanced malignancy . J Clin Oncol . 2005 ; 23 : 2130-2135 . 12 . Meyer G , Marjanovic Z , Valcke J , Lorcerie B , Gruel Y , Solal-Celigny P , Le Maignan C , Extra JM , Cottu P , Farge D. Comparison low-molecular-weight heparin warfarin secondary prevention venous thromboembolism patient cancer : randomize control study . Arch Intern Med . 2002 ; 162:1729-1735 . 13 . Casu B , Lindahl U . Structure biological interaction heparin heparan sulfate . Adv Carbohydr Chem Biochem . 2001 ; 57 : 159-206 . 14 . Parish CR , Freeman C , Hulett MD . Heparanase : key enzyme involve cell invasion . Biochim Biophys Acta . 2001 ; 1471 : M99-108 . 15 . Vlodavsky I , Friedmann Y. Molecular property involvement heparanase cancer metastasis angiogenesis . J Clin Invest . 2001 ; 108 : 341-347 . 16 . Nakajima M , Irimura T , Nicolson GL . Heparanases tumor metastasis . J Cell Biochem . 1988 ; 36:157-167 . 17 . Dempsey LA , Brunn GJ , Platt JL . Heparanase , potential regulator cell-matrix interaction . Trends Biochem Sci . 2000 ; 25 : 349-351 . 18 . Levy-Adam F , Miao HQ , Heinrikson RL , Vlodavsky I , Ilan N. Heterodimer formation essential heparanase enzymatic activity . Biochem Biophy Res Commun . 2003 ; 308 : 885-891 . 19 . Vlodavsky I , Friedmann Y , Elkin M , Aingorn H , Atzmon R , Ishai-Michaeli R , Bitan M , Pappo O , Peretz T , Michal I , Spector L , Pecker I. Mammalian heparanase : gene cloning , expression function tumor progression metastasis . Nat Med . 1999 ; 5 : 793-802 . 20 . Shafat I , Zchria E , Nisman B , Nadir Y , Nakhoul F , Vlodavsky I , Ilan N. An ELISA method detection quantification human heparanase . Biochem Biophy Res Commun . 2006 ; 341 : 958-963 . 21 . Vlodavsky I , Mohsen M , Lider O , Svahn CM , Ekre HP , Vigoda M , Ishai-Michaeli R , Peretz T. Inhibition tumor metastasis heparanase inhibit specie heparin . Invasion Metastasis . 1994 ; 14 : 290-302 . 22 . Parish CR , Coombe DR , Jakobsen KB , Bennett FA , Underwood PA . Evidence sulphated polysaccharide inhibit tumour metastasis block tumour-cell-derived heparanases . Int J Cancer . 1987 ; 40 : 511-518 . 23 . Parish CR , Freeman C , Brown KJ , Francis DJ , Cowden WB . Identification sulfate oligosaccharide-based inhibitor tumor growth metastasis use novel vitro assay angiogenesis heparanase activity . Cancer Res . 1999 ; 59 : 3433-3441 . 24 . Miao HQ , Elkin M , Aingorn E , Ishai-Michaeli R , Stein CA , Vlodavsky I. Inhibition heparanase activity tumor metastasis laminarin sulfate synthetic phosphorothioate oligodeoxynucleotides . Int J Cancer . 1999 ; 83 : 424-431 . 25 . Nasser NJ , Sarig G , Brenner B , Nevo E , Goldshmidt O , Zcharia E , Li JP , Vlodavsky I. Heparanase neutralize anticoagulation property heparin low-molecular-weight heparin . J Thromb Haemost . 2006 ; 4 : 560-565 . 26 . Levy JH . Heparin resistance antithrombin : still call heparin resistance ? Journal cardiovascular anesthesia . 2004 ; 18 : 129-130 . 27 . Deitcher SR. Cancer thrombosis : mechanisms treatment . J Thromb Thrombolysis . 2003 ; 16 : 21-31 . 28 . Gohji K , Hirano H , Okamoto M , Kitazawa S , Toyoshima M , Dong J , Katsuoka Y , Nakajima M. Expression three extracellular matrix degradative enzyme bladder cancer . Int J Cancer . 2001 ; 95 : 295-301 . 29 . Koliopanos A , Friess H , Kleeff J , Shi X , Liao Q , Pecker I , Vlodavsky I , Zimmermann A , Buchler MW . Heparanase expression primary metastatic pancreatic cancer . Cancer Res . 2001 ; 61 : 4655-59 . 30 . Kim AW , Xu X , Hollinger EF , Gattuso P , Godellas CV , Prinz RA . Human heparanase-1 gene expression pancreatic adenocarcinoma . J Gastrointest Surg . 2002 ; 6 : 167-172 .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Treatment therapeutic dose low molecular weight heparin Serum creatinine level &lt; 1.5 mg/dl . major surgery last month investigation evidence major infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Condition</keyword>
	<keyword>Cancer</keyword>
	<keyword>Patients</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Unstable</keyword>
	<keyword>Angina</keyword>
	<keyword>Pectoris</keyword>
</DOC>